Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

Insulin degludec, an ultra-long-acting b

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

✍ Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Jo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 203 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

## Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. we aimed to compare combined insulin degludec-liraglutide (ideglira

The Efficacy and Safety of Insulin Deglu

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

✍ Meneghini, L.; Atkin, S. L.; Gough, S. C. L.; Raz, I.; Blonde, L.; Shestakova, M 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 842 KB

Insulin degludec, an ultra-longacting ba

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

✍ Alan J Garber; Allen B King; Stefano Del Prato; Seamus Sreenan; Mustafa K Balci; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 284 KB

Low-Volume Insulin Degludec 200 Units/mL

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

✍ Gough, S. C. L.; Bhargava, A.; Jain, R.; Mersebach, H.; Rasmussen, S.; Bergensta 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 443 KB